Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | CALCR | P30988 | 7/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | FCGRT | P55899 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454445 | 0.86 | CAPN1 (0.46) | APLNRF2SLC6A2CAPN1 | |
| SCHEMBL29608153 | 0.83 | REN (0.51) | F2SLC6A2 | |
| SCHEMBL30679585 | 0.83 | CALCR (0.55) | APLNRF2CALCRHCRTR1HCRTR2 | |
| SCHEMBL29608127 | 0.83 | REN (0.49) | F2CALCRSLC6A2CAPN1 | |
| SCHEMBL30455333 | 0.83 | F2 (0.52) | APLNRF2CALCRC5AR1 | |
| SCHEMBL29384601 | 0.82 | SLC6A2 (0.52) | APLNRF2CALCRSLC6A2RAMP3 | |
| SCHEMBL30884598 | 0.80 | RAMP3 (0.61) | APLNRF2CALCRC5AR1RAMP3 | |
| SCHEMBL29607579 | 0.80 | SLC6A2 (0.49) | APLNRF2CALCRSLC6A2CAPN1 | |
| SCHEMBL31124516 | 0.80 | F2 (0.46) | APLNRF2 | |
| SCHEMBL31124515 | 0.80 | F2 (0.46) | APLNRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | claimed |
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (OR) | 2024-10-17 | — | — | US | disclosed |
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | ARGLU1, TPX2, RXFP1 | APLNR 122/4885F2 2604/4885CALCR 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.